Jonathan A. Ledermann

Jonathan Ledermann is Professor of Medical Oncology at the UCL Cancer Institute and one of the world's foremost authorities on ovarian cancer clinical trials, particularly in the development of PARP inhibitor maintenance therapy. He led the landmark SOLO1 and SOLO2 trials evaluating olaparib as maintenance therapy in BRCA-mutated ovarian cancer patients, which established a new paradigm for first-line and recurrent disease management. These trials provided pivotal evidence supporting regulatory approvals of olaparib in Europe and globally. Ledermann has had a distinguished career as a clinical trialist and translational researcher, combining expertise in biomarker-driven patient selection with rigorous clinical study design. His work on BRCA mutation status and homologous recombination deficiency (HRD) as predictors of PARP inhibitor benefit has shaped how gynecologic oncologists stratify patients for maintenance treatment decisions. He has been a principal investigator on dozens of cooperative trials through the GCIG (Gynecologic Cancer InterGroup) and ICON (International Collaboration on Ovarian Neoplasms) groups. Beyond PARP inhibitors, Ledermann has contributed to understanding of antiangiogenic therapy, chemotherapy optimization, and biomarker development in ovarian cancer. He has served in editorial and advisory roles for major oncology journals and organizations, and is recognized internationally for advancing evidence-based gynecologic oncology.